Virtual Network's Login.
Chairpersons: Pierre Fenaux, Eva Hellström-Lindberg, David P. Steensma
Session I : Diagnosis
Anna Porwit, Arjan A. Van de Loosdrecht , Torsten Haferlach
Session II: Prognosis
Luca Malcovati, Raphaël Itzykson, Arjan A. Van de Loosdrecht, Torsten Haferlach, Luca Malcovati
Session III: Treatment of lower risk MDS (non del 5q)
David P. Steensma, Eva Hellström-Lindberg, Aristoteles Giagounidis
Session IV: Treatment of higher risk MDS (except allo SCT)
Lionel Adès, Uwe Platzbecker, Valeria Santini
Session V: Allogeneic SCT
Nicolaus Kröger, Guillermo F. Sanz
Session VI: Overview of new drugs, clinical trials, and international cooperative efforts in clinical research
Valeria Santini, Uwe Platzbecker, Arjan A. Van de Loosdrecht, David P. Steensma , Pierre Fenaux
Session VII: Molecularly defined MDS and MDS/MPN
a) Lower risk MDS with del 5q – Aristoteles Giagounidis, Eva Hellström-Lindberg
b) MDS and MDS/MPN with ringed sideroblasts – Luca Malcovati
c) CMML – Raphaël Itzykson, Pierre Fenaux
d) Treatment of thrombocytopenia in lower risk MDS – Aristoteles Giagounidis
